It’s with pleasure to inform you that LDN has launched ELISAs for the semi-quantitative detection of:
COVID-19 (SARS-CoV-2) IgM and
COVID-19 (SARS-CoV-2) IgG
COVID-19 (Corona Virus Disease) is caused by 2019-nCoV (SARS-CoV-2) which is mainly transmitted through respiratory droplets. Symptoms of COVID-19 may appear 1-14 days after exposure and mainly include: fever, cough and shortness of breath.
Currently, RT-PCR tests are being used to diagnose the patients worldwide because of its availability. However, RT-PCR based diagnosis has its limitation.
Detecting SARS-CoV-2 by RT-PCR requires high-quality nasopharyngeal specimens that contain an enough amount of intact viral RNA. The challenges associated with collection of this specimen type has led to many reported high false-negative rates.
The advantage of immunoassays is their ability to detect recent and past infections. IgG antibodies are long-lasting and can persist in the bloodstream for many years after infection. This test has the advantage of detecting not only individuals with active infection, but also those who were previously exposed to the virus and have subsequently developed immunity. <<LDN-Flyer>>
LDN offers easy-to-use ELISAs for the detection of Covid-19 specific IgM <<ID E-1100 IFU>> and Covid-19 specific IgG <<ID E-1000 IFU>> which specifically detect antibodies against the new SARS-CoV-2 virus.
In summary, our assays show the following advantages:
- CE-marked; for IVD
- Specific and sensitive detection of antibodies against SARS-CoV-2 virus
- IgM-assay designed with “IgM capture” method
- Results within 1.5 hours
- Samples can be stored – no need to run the same day of blood withdrawal
Request a Quote: email@example.com